Richard M. Stone | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Richard M. Stone is active.

Explore More

Publication

Featured researches published by Richard M. Stone.

Blood | 2000

Report of an international working group to standardize response criteria for myelodysplastic syndromes

Bruce D. Cheson; John M. Bennett; Hagop M. Kantarjian; A. Pinto; Charles A. Schiffer; Stephen D. Nimer; B Lowenberg; M. Beran; T. M. De Witte; Richard M. Stone; Moshe Mittelman; Guillermo Sanz; Pierre W. Wijermans; Stacey M. Gore; Peter L. Greenberg

Archive | 2003

Acute Myeloid Leukemia in Adults

Charles A. Schiffer; Richard M. Stone

Blood | 2001

Myelodysplastic syndromes standardized response criteria: further definition.

Bruce D. Cheson; John M. Bennett; Hagop M. Kantarjian; Charles A. Schiffer; Stephen D. Nimer; B Lowenberg; Richard M. Stone; Moshe Mittelman; Guillermo Sanz; Pierre W. Wijermans; Peter L. Greenberg

Archive | 2003

Presenting Signs and Symptoms

Charles A. Schiffer; Richard M. Stone

Stem/Initiating Cells in Hematologic Malignancies | 2017

Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs

Julia Etchin; Alla Berezovskaya; Amy Saur Conway; Ilene Galinsky; Richard M. Stone; Erkan Baloglu; William Senapedis; Yosef Landesman; Michael Kauffman; Sharon Shacham; Jean Cy Wang; A. Thomas Look

Chemical Biology | 2017

Abstract PR04: Degradation of leukemia oncogenes: A novel approach to therapy of leukemia

Sara J. Buhrlage; Ellen Weisberg; Ilaria Lamberto; Jing Yang; Nathan J. Schauer; Martin Sattler; Atushi Nonami; Amanda L. Christie; David M. Weinstock; Stella Ritorto; Virginia DeCesare; Matthias Trost; Richard M. Stone; Nathanael S. Gray; James D. Griffin

Archive | 2013

with standard-dose cytarabine a randomized trial comparing mitoxantrone and intermediate-dose cytarabine Postremission therapy in older patients with de novo acute myeloid leukemia:

Charles A. Schiffer; Edward J. Lee; Joseph O. Moore; Bayard L. Powell; Maria R. Baer; Clara D. Bloomfield; Richard M. Stone; Deborah T. Berg; Stephen L. George; Richard K. Dodge; Paolo Alberto Paciucci

Archive | 2013

leukemia Endpoints to establish the efficacy of new agents in the treatment of acute

Nancy S. Scher; Franklin O. Smith; Richard M. Stone; Martin S. Tallman; Stephen J. Forman; Richard A. Larson; Stephanie J. Lee; Sharon B. Murphy; Susan O'Brien; R. Appelbaum; Daniel Rosenblum; Robert J. Arceci; William L. Carroll; Philip P. Breitfeld

Archive | 2013

respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3

Jennifer J. Clark; D. Gary Gilliland; James D. Griffin; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A. Fox; Donna Neuberg; Richard M. Stone; Daniel J. DeAngelo; Ilene Galinsky; E. Estey; Stephen D. Nimer

Archive | 2013